We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive complete results from the ENVISION phase III study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).
In the study, givosiran met the primary efficacy endpoint, with a 74% mean reduction relative to placebo in the annualized rate of composite porphyria attacks. There was a corresponding 90% median reduction in composite annualized attack rate (AAR), with a median AAR of 1.0 in givosiran patients compared with a median AAR of 10.7 in placebo patients. In the trial, 50% of givosiran-treated patients were attack-free during the six-month treatment period as compared to 16.3% of placebo-treated patients.
Givosiran also achieved statistically significant positive results for five out of nine secondary endpoints, with an overall safety and tolerability profile. Adverse events (AEs) were reported in 89.6% of givosiran patients and 80.4% of placebo patients, while serious adverse events (SAEs) were reported in 20.8% of givosiran patients and 8.7% of placebo patients.
Shares of Alnylam have rallied 23.9% in the past year compared with the industry’s growth of 8.8%.
In March 2019, the company released ENVISION study data, where givosiran met the main goal of reducing the yearly number of attacks in patients with acute intermittent porphyria (AIP).
In October 2018, Alnylam announced positive early results from the interim analysis of the ENVISION phase III study. The results showed that treatment with givosiran led to a statistically significant reduction in urinary aminolevulinic acid (ALA) levels in AIP patients compared to placebo. The study also showed SAEs in 22% of givosiran patients and 10% of placebo patients in the interim analysis cohort of 43 patients, with one patient (4%) on givosiran discontinuing the treatment due to an increase in liver transaminase that was resolved.
The open-label extension (OLE) period of the study has already enrolled 99% of patients. Based on the ENVISION results, the company plans to complete its rolling submission of a new drug application (NDA) and file a Marketing Authorization Application (MAA) in mid-2019.
We remind investors that the company’s only approved drug, Onpattro, is a first-of-its-kind RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug is the first and only FDA-approved treatment for this indication.
Alnylam also has other candidates in its pipeline. The company along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate have allowed it to enter collaborations with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche, Takeda, Merck, The Medicines Company and Sanofi’s specialty care global business unit, Genzyme, among others.
Recently, Alnylam and Regeneron Pharmaceuticals (REGN - Free Report) extended their collaboration agreement. Both the companies will work together to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive complete results from the ENVISION phase III study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).
In the study, givosiran met the primary efficacy endpoint, with a 74% mean reduction relative to placebo in the annualized rate of composite porphyria attacks. There was a corresponding 90% median reduction in composite annualized attack rate (AAR), with a median AAR of 1.0 in givosiran patients compared with a median AAR of 10.7 in placebo patients. In the trial, 50% of givosiran-treated patients were attack-free during the six-month treatment period as compared to 16.3% of placebo-treated patients.
Givosiran also achieved statistically significant positive results for five out of nine secondary endpoints, with an overall safety and tolerability profile. Adverse events (AEs) were reported in 89.6% of givosiran patients and 80.4% of placebo patients, while serious adverse events (SAEs) were reported in 20.8% of givosiran patients and 8.7% of placebo patients.
Shares of Alnylam have rallied 23.9% in the past year compared with the industry’s growth of 8.8%.
In March 2019, the company released ENVISION study data, where givosiran met the main goal of reducing the yearly number of attacks in patients with acute intermittent porphyria (AIP).
In October 2018, Alnylam announced positive early results from the interim analysis of the ENVISION phase III study. The results showed that treatment with givosiran led to a statistically significant reduction in urinary aminolevulinic acid (ALA) levels in AIP patients compared to placebo. The study also showed SAEs in 22% of givosiran patients and 10% of placebo patients in the interim analysis cohort of 43 patients, with one patient (4%) on givosiran discontinuing the treatment due to an increase in liver transaminase that was resolved.
The open-label extension (OLE) period of the study has already enrolled 99% of patients. Based on the ENVISION results, the company plans to complete its rolling submission of a new drug application (NDA) and file a Marketing Authorization Application (MAA) in mid-2019.
We remind investors that the company’s only approved drug, Onpattro, is a first-of-its-kind RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug is the first and only FDA-approved treatment for this indication.
Alnylam also has other candidates in its pipeline. The company along with partner The Medicine Company is evaluating inclisiran in phase III ORION studies for hypercholesterolemia.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate have allowed it to enter collaborations with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche, Takeda, Merck, The Medicines Company and Sanofi’s specialty care global business unit, Genzyme, among others.
Recently, Alnylam and Regeneron Pharmaceuticals (REGN - Free Report) extended their collaboration agreement. Both the companies will work together to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>